{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:06:52Z","timestamp":1753895212231,"version":"3.41.2"},"reference-count":4,"publisher":"American College of Physicians","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.acpjournals.org\/journal\/aim\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Intern Med"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.7326\/annals-25-02312-jc","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T17:00:32Z","timestamp":1751302832000},"page":"JC76","source":"Crossref","is-referenced-by-count":0,"title":["In adults with clinically isolated syndrome suggestive of MS, high-dose vitamin D monotherapy reduced disease activity at 2 y"],"prefix":"10.7326","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-3393","authenticated-orcid":false,"given":"Lucas H.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Virginia Mason Franciscan Health, Seattle, Washington, USA (L.H.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ACP Journal Club Editorial Team at McMaster University","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4285","reference":[{"key":"ANNALS-25-02312-R1","doi-asserted-by":"crossref","unstructured":"Cassard SD, Fitzgerald KC, Qian P, et al. High-dose vitamin D3 supplementation in relapsing\u2013remitting multiple sclerosis: a randomised clinical trial. EClinicalMedicine. 2023;59:101957. [PMID: 37125397]","DOI":"10.1016\/j.eclinm.2023.101957"},{"key":"ANNALS-25-02312-R2","doi-asserted-by":"crossref","unstructured":"Hupperts R, Smolders J, Vieth R, et al; SOLAR Study Group. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon \u03b2-1a. Neurology. 2019;93:e1906-e1916. [PMID: 31594857]","DOI":"10.1212\/WNL.0000000000008445"},{"key":"ANNALS-25-02312-R3","doi-asserted-by":"crossref","unstructured":"Camu W, Lehert P, Pierrot-Deseilligny C, et al. Cholecalciferol in relapsing\u2013remitting MS: a randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm. 2019;6:e597. [PMID: 31454777]","DOI":"10.1212\/NXI.0000000000000597"},{"key":"ANNALS-25-02312-R4","doi-asserted-by":"crossref","unstructured":"Butzkueven H, Ponsonby AL, Stein MS, et al; PREVANZ Investigators. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain. 2024;147:1206-1215. [PMID: 38085047]","DOI":"10.1093\/brain\/awad409"}],"container-title":["Annals of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.acpjournals.org\/doi\/pdf\/10.7326\/ANNALS-25-02312-JC","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.acpjournals.org\/doi\/full-xml\/10.7326\/ANNALS-25-02312-JC","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T21:02:10Z","timestamp":1752526930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.acpjournals.org\/doi\/10.7326\/ANNALS-25-02312-JC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":4,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.7326\/ANNALS-25-02312-JC"],"URL":"https:\/\/doi.org\/10.7326\/annals-25-02312-jc","relation":{},"ISSN":["0003-4819","1539-3704"],"issn-type":[{"type":"print","value":"0003-4819"},{"type":"electronic","value":"1539-3704"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}